Document Detail

Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.
MedLine Citation:
PMID:  21833531     Owner:  NLM     Status:  MEDLINE    
(1) To compare the serum levels of Dickkopf-1 (DKK-1) and bone biomarkers in patients with ankylosing spondylitis (AS) and healthy controls. (2) To examine the effects of anti-tumor necrosis factor-α (TNF-α) therapy for 3 months on bone biomarkers in patients with AS. We measured the levels of DKK-1, osteocalcin, osteoprotegerin, and C-terminal telopeptide of type I collagen (CTX-1) in patients with AS and in healthy controls at baseline and 3 months after initiating anti-TNF-α therapy in AS patients. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were also measured before and after anti-TNF-α therapy in AS patients. Serum levels of DKK-1 were significantly lower in the AS patients than in the controls (P < 0.0001). Osteocalcin and osteoprotegerin levels were significantly higher in the AS patients than in the controls (P < 0.0001). Serum levels of DKK-1 were not changed after the 3-month anti-TNF-α therapy. Osteocalcin level increased (P < 0.0001), osteoprotegerin level and BASDAI scores decreased (P = 0.025 and P < 0.0001, respectively) significantly after the 3-months anti-TNF-α therapy. Serum DKK-1 level was lower in patients with AS than in healthy controls and did not change after 3 months of anti-TNF-α therapy in the AS patients despite the marked improvement in BASDAI scores. These findings suggest the low serum DKK-1 level is related to the pathogenesis of new bone formation in AS, which is resistant to TNF-α blocking therapy.
Seong-Ryul Kwon; Mie-Jin Lim; Chang-Hee Suh; Shin-Goo Park; Yeon-Sik Hong; Bo-Young Yoon; Hyoun-Ah Kim; Hyo-Jin Choi; Won Park
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-07-16
Journal Detail:
Title:  Rheumatology international     Volume:  32     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-24     Completed Date:  2012-12-07     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  2523-7     Citation Subset:  IM    
Rheumatism Center, Inha University Hospital, 3rd street Sinheung-dong, Jung-gu, Incheon 400-711, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Biological Markers / blood
Case-Control Studies
Collagen Type I / blood
Immunoglobulin G / therapeutic use
Immunologic Factors / therapeutic use*
Intercellular Signaling Peptides and Proteins / blood*
Middle Aged
Osteocalcin / blood
Osteogenesis / drug effects
Osteoprotegerin / blood
Peptides / blood
Receptors, Tumor Necrosis Factor / therapeutic use
Republic of Korea
Severity of Illness Index
Spondylitis, Ankylosing / blood*,  diagnosis,  drug therapy*,  immunology
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Biological Markers; 0/Collagen Type I; 0/DKK1 protein, human; 0/Immunoglobulin G; 0/Immunologic Factors; 0/Intercellular Signaling Peptides and Proteins; 0/Osteoprotegerin; 0/Peptides; 0/Receptors, Tumor Necrosis Factor; 0/TNFRSF11B protein, human; 0/Tumor Necrosis Factor-alpha; 0/collagen type I trimeric cross-linked peptide; 0/infliximab; 104982-03-8/Osteocalcin; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is Still's disease still one disease? A case of Adult-onset Still's disease showing accumulation in ...
Next Document:  Modulation of immune and inflammatory responses on experimental arthritis following intraarticular g...